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Abstract Chronic neuropathic pain (CNP) is one of the most
significant unmet clinical needs in modern medicine.
Alongside the lack of effective treatments, there is a great
deficit in the availability of objective diagnostic methods to
reliably facilitate an accurate diagnosis. We therefore aimed to
determine the feasibility of a simple diagnostic test by
analysing differentially expressed genes in the blood of pa-
tients diagnosed with CNP of the lower back and compared to
healthy human controls. Refinement of microarray expression
data was performed using correlation analysis with 3900 hu-
man 2-colour microarray experiments. Selected genes were
analysed in the dorsal horn of Sprague–Dawley rats after L5
spinal nerve ligation (SNL), using qRT-PCR and ddPCR, to
determine possible associations with pathophysiological
mechanisms underpinning CNP and whether they represent
translational biomarkers of CNP. We found that of the 15
potential biomarkers identified, tissue inhibitor of matrix
metalloproteinase-1 (TIMP1) gene expression was upregulat-
ed in chronic neuropathic lower back pain (CNBP)
(p = 0.0049) which positively correlated (R = 0.68,
p = ≤0.05) with increased plasma TIMP1 levels in this group
(p = 0.0433). Moreover, plasma TIMP1 was also significantly
upregulated in CNBP than chronic inflammatory lower back
pain (p = 0.0272). In the SNL model, upregulation of the
Timp1 gene was also observed (p = 0.0058) alongside a strong
trend for the upregulation of melanocortin 1 receptor
(p = 0.0847). Our data therefore highlights several genes that
warrant further investigation, and of these, TIMP1 shows the
greatest potential as an accessible and translational CNP
biomarker.
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Introduction
Chronic neuropathic pain (CNP) is a physically debilitating
and pathologically complex disorder featuring maladaptive
cellular responses and the subsequent development of ectopic
discharge and neuronal hyperexcitability [1]. This manifests
as allodynia and hyperalgesia in up to 50% of patients with
CNP [2]. CNP is often a consequence of traumatic nerve in-
jury but is also associated with numerous peripheral and cen-
trallymediated factors, such as diabetes, multiple sclerosis and
stroke [3, 4], and results in a complex plethora of CNP sub-
types including chronic neuropathic lower back pain.
Therefore, CNP diagnosis is inherently complex and remains
subjective, with the primary methods for diagnosis being the
painDETECT [5], Neuropathic Pain Questionnaire (NPQ) [6]
and the Leeds Assessment of Neuropathic Symptoms and
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Signs (LANSS) screening tools [7], alongside clinical assess-
ment. The stark deficit in effective treatments and objective
diagnostic tools therefore provides the impetus to determine
novel and translational diagnostic biomarkers to promote ear-
ly intervention in CNP.
There is a growing body of evidence which suggests an
increasing involvement of non-neuronal mechanisms in the
pathophysiology of CNP. These often pertain to the immune
system to such a degree that CNP has been considered a
neuro-immune disorder with glial cell and cytokine involve-
ment [8, 9]. The diversity, complexity and involvement of
these non-neuronal mechanisms associated with CNP may
therefore herald the opportunity to determine an accessible
biomarker in blood. Much of the research searching for CNP
biomarkers in humans to date has considered cerebrospinal
fluid [10] and the brain [11] with functional magnetic reso-
nance imaging (fMRI) being proposed as a way of determin-
ing CNS biomarkers to guide clinical practice [12]. However,
such methodology is likely to be impractical as acceptable and
cost-effective method of biomarker detection in clinical
practice.
The majority of gene expression studies have focused sole-
ly on animal models of neuropathic pain (NP) [13], ranging
from chronic constriction injury (CCI) [14] and spinal nerve
ligation (SNL) [15] to the spared nerve injury [16] and drug-
induced neuropathy [17] models. Such studies have identified
extensive groups of genes whose expression is altered after
nerve injury [18] and have provided valuable insights into the
mechanisms underpinning the development and maintenance
of CNP. Little though has been translated to advances in diag-
nostic biomarkers in human CNP subjects. A pertinent previ-
ous study sought to elucidate biomarkers by determining cor-
relations in gene expression changes between rat blood and
ipsilateral lumbar dorsal quadrant (iLDQ) after CCI, using
bioinformatics in conjunction with microarray analysis, which
demonstrated the potential of blood transcriptomic changes as
peripheral markers to reflect those in the iDLQ after nerve
injury [19].
In order to bridge this gap to humans, we sought to deter-
mine the feasibility of a minimally invasive method of sample
collection by performing microarray analysis to establish a
panel of genes differentially expressed in blood from a cohort
of patients diagnosed with CNP of the lower back and healthy
human controls. Due to the complexities of CNP, we focused
our study on the chronic lower back pain (CLBP) of neuro-
pathic origin. CLBP is a common chronic pain condition and
has been estimated to account for the biggest proportion of the
chronic pain market [20]. Moreover, ∼85% of CLBP patients
are grouped as non-specific CLBP [21], and at present, there is
a lack of objective diagnostic tools to determining if this non-
specific CLBP group is of a neuropathic or inflammatory or-
igin. Thus, there is a clear need to identify biomarkers that can
help delineate these subtypes that could also potentially
provide insight into other CNP subtypes and pain conditions.
After our initial array analysis in human samples, we investi-
gated the expression of a subset of the candidate genes iden-
tified in the dorsal horn of sham and L5 SNL Sprague–
Dawley rats. This strategy therefore prioritised the search for
viable biomarkers in human blood whilst determining if these
biomarkers are translational across species. The L5 SNL
Sprague–Dawley rat model was chosen as the translational
model of CNP as symptoms generated in in this systemmimic
the neuropathic pain symptoms of human patients [15, 17].
Furthermore, we focused on the dorsal horn region of the
spinal cord as these neurons process sensory information
and undergo changes that contribute to the development and
maintenance of neuropathic pain [22]. Using the translational
approach to biomarker discovery also highlights whether
these molecules may be perturbed in the mechanisms under-
pinning CNP and therefore whether theymay hold potential as
disease phenotypic indicators and/or pharmacological targets
in preclinical analgesic drug development.
Materials and Methods
Human Clinical Samples
PAXgene Blood RNA Tubes (IVD; PreAnalytiX GmbH,
Hombrechtikon, Switzerland) from 10 individuals with chron-
ic neuropathic lower back pain (CNBP) lasting for more than
6 months were obtained through ProteoGenex tissue procure-
ment services (Culver City, CA), alongside a further 10 age-
gender matched controls also acquired through ProteoGenex
tissue procurement services. Patients were recruited after clin-
ical assessment of their pain symptoms, including CT scans,
MRI scans and electroneuromyography. Pain intensities were
determined using the verbal rating scale (VRS) [23]. All pa-
tients were non-responsive to non-narcotic and anti-
inflammatory analgesics. Plasma was obtained using BD
Vacutainer K2-EDTA tubes with centrifugation at 1000×g
for 10 min and immediate storage of the plasma at −80 °C.
Patients with major psychiatric disorders, cancer or diabetes
were excluded from this study. Donor consent was obtained
through ProteoGenex under Protocol PG-ONG2003/1, titled
Collection of Tissue, Blood and Bone Marrow. Plasma from a
total of 12 patients with chronic inflammatory back pain
(CIBP) was also obtained to delineate between a potential
translational biomarker of CNBP and one of CIBP. The ab-
sence of CNBP was determined by consultant assessment and
the post-consultation completion of the S-LANSS question-
naire, which allows delineation between nociceptive and neu-
ropathic pain [24] and shows good correlation with other
screening tools for lower back-related pain [25]. Patients with
an S-LANSS score of 12 or greater were excluded. Pain se-
verity was determined using the Chronic Pain Grade
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questionnaire [26] and is presenting with demographic data on
the patient and control groups (Supplementary Table 1).
RNA Isolation
Total RNAwas isolated from the PAXgene Blood RNATubes
using the Preserved Blood RNA Purification Kit II (Norgen,
Biotek, ON, Canada) according to the manufacturer’s instruc-
tions. In brief, the RNAwas treated with DNAse and purified
on columns. RNA concentration was measured on a
NanoDrop ND2000 ultraviolet–visible spectrophotometer
(Labtech International Ltd., UK), and RNA integrity was
checked on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Amsterdam, The Netherlands). RNA was
judged as suitable for gene expression analysis only if samples
showed intact bands of 28S and 18S ribosomal RNA subunits,
displayed no chromosomal peaks or RNA degradation prod-
ucts and had an RNA integrity number (RIN) above 7.0.
Affymetrix Microarray and Data Analysis
Total RNAwas labeled using an Ambion WT Expression kit
(Life Technologies, Bleiswijk, The Netherlands) and
hybridised to Affymetrix Human Gene 1.0 ST expression ar-
rays (Affymetrix, Santa Clara, CA, USA). Sample labeling,
hybridization to chips and image scanning were performed
according to the manufacturer’s instructions on an
Affymetrix GeneTitan instrument. Quality control was per-
formed using Affymetrix Expression Console, and interpreta-
tion of data was facilitated by Affymetrix Transcriptome
Analysis Console 2.0 (TAC2.0). Transcripts exhibiting a fold
change of ≥1.2 and a p value of ≤0.05 (ANOVA) were con-
sidered differentially expressed and suitable for further corre-
lation analysis and refinement.
Analysis of General Gene–Gene Correlations
A total of 3900 human 2-colour microarray experiments were
downloaded from NCBI’s Gene Expression Omnibus (GEO)
and normalised as described previously [27]. The experiments
span different tissues and different conditions—these 3900
were chosen because it is the subset of all 2-colour arrays that
have been curated by NCBI staff. Two-colour arrays were
chosen because they reflect how gene expression differs be-
tween two conditions, usually experimental and control,
which emphasises how genes are correlated in their response.
Gene–gene Pearson’s correlation coefficients were calculated
using only the experiments where the two genes were present
on the same microarray.
Further Refinement of Expression Data
In order to determine the genes with the greatest evidence for
involvement in CNBP, refinement of genes was undertaken
with specified criteria, which includes a greater statistical
stringency (Table 1), the presence of a gene within our corre-
lation analysis output, and finally, whether there is a body of
literature pertaining to the role of the molecule in pain path-
ways. Literature was searched to include all publications
available up to, and including, February 2017, using both
Table 1 CNP biomarker panel of transcripts differentially regulated in human whole blooda
Array ID Accession number Gene name Gene symbol p value FC in CNP CA Literature
7951385 NM_004347 Caspase 5 CASP5 0.0449 ↑2.23 No [39, 40]
8149927 NM_001831 Clusterin CLU 0.0489 ↑1.85 No [41, 42]
7941621 NM_005700 Dipeptidyl-Peptidase 3 DPP3 0.0028 ↑1.50 No [37, 38, 43, 44]
7908793 NM_004433 E74-Like Factor 3 ELF3 0.0095 ↑1.62 No [45, 46]
7937707 NR_026643 Family with sequence similarity 99, member A FAM99A 0.0017 ↑1.64 No –
8070720 NM_015259 Inducible T cell co-stimulator ligand ICOSLG 0.0007 ↑1.20 No [19]
8065011 NM_024674 Lin-28 homolog A (C. elegans) LIN28A 0.0183 ↓1.50 No [47]
7998055 NM_002386 Melanocortin 1 Receptor MC1R 0.0005 ↑1.40 No [48–53]
8051396 NM_021209 NLR family CARD domain-containing protein 4 NLRC4 0.0437 ↑1.99 No [54]
8157450 NM_000608 Orosomucoid 2 ORM2 0.0225 ↑1.97 Yes –
7982287 NM_001039841 Rho GTPase activating protein 11B ARHGAP11B 0.0025 ↑1.57 No –
8075477 NM_152267 Ring finger protein 185 RNF185 0.0032 ↓1.68 No –
7967972 NG_043316 RNA, U6 small nuclear 76, Pseudogene RNU6-76P 0.0049 ↓1.54 No –
8167185 NM_003254 TIMP metalloproteinase Inhibitor 1 TIMP1 0.0049 ↑1.50 Yes [35, 36, 55–60]
7924499 NM_003268 Toll-like receptor 5 TLR5 0.0428 ↑1.75 No [61, 62]
a Genes documented here and subsequently analysed in the SNL model either exhibited a p value of ≤0.005 and a fold change (FC) of ≥1.5 or were
present in our correlation analysis (CA)/literature search with a p value of 0.005–0.05 and a FC of ≥1.5 or a p value of ≤0.005 and a FC of 1.2–1.5
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PubMed and general electronic information databases with the
gene name or symbol, along with the terms ‘pain’, ‘neuropath-
ic’ or ‘neuropathic pain’.
Plasma TIMP1 Quantification
In order to clarify if circulating levels of tissue inhibitor of
matrix metalloproteinase-1 (TIMP1) varied between patients
with CNBP, CIBP and healthy controls, a total of 32 plasma
samples were subject to a TIMP1 enzyme-linked immunosor-
bent assay (ELISA) (Invitrogen, UK). The assay was per-
formed according to manufacturer’s instructions. In total,
10 μl of plasma was diluted to 200 μl prior to the procedure,
each sample was analysed in duplicate and absorbance data
was obtained using an Infinite F50 microplate reader (Tecan,
UK). Absorbance data were converted into plasma TIMP1
levels using the standards provided, and the data were
analysed using GraphPad Prism 6.0 using a Mann–Whitney
test and Kruskal–Wallis test (p = ≤0.05 considered statistically
significant).
Animal Husbandry, L5 SNL Surgery and Tissue Harvest
Adult male Sprague–Dawley rats (n = 18) (matched at 7–
8 weeks of age upon delivery and 250–350 g at time of ex-
perimentation; Harlan, UK) were housed singly, with food and
water available ad libitum and maintained at constant temper-
ature (21 ± 2 °C) under 12 h cycling of light–dark exposure
(lights on at 07.00 h). The e xperimental procedures were
approved by the Animal Care and Research Ethics
Committee, National University of Ireland, Galway, and car-
ried out under license from the Department of Health in the
Republic of Ireland and in accordance with EU Directive
2010/63. One week following delivery and acclimatization
to the animal unit, animals underwent surgery after allocation
into either L5 SNL (n = 10) or sham (n = 8) groups. In brief,
the rats were anaesthetised under isoflurane anaesthesia (3%
induction, 1.5–2% maintenance in 0.5 L/min O2), and upon
exposure of the left L5 spinal nerve, a ligature was applied.
Sham rats were treated identically, aside from ligation of the
L5 nerve. Animals were maintained until 35 days post-surgery
at which point euthanasia was performed by decapitation and
tissue was harvested from the spinal cord dorsal horn ipsilat-
eral to the side of nerve injury, snap-frozen on dry ice and
stored at −80 °C. RNA was extracted from tissue using the
NucleoSpin® RNA kit (Machery–Nagel) with on-column
DNase treatment followed by storage at −80 °C.
Quantitative Real-Time PCR
A total of 20 ng of RNA from each dorsal horn sample was
used for reverse transcription and subsequent amplification
using the QuantiTect Whole Transcriptome Kit (Qiagen,
UK). This was performed according to manufacturer’s in-
structions and included an 8-h incubation stage for high yield
cDNA synthesis. After serial dilution of the amplification
product, quantitative real-time polymerase chain reaction
(qRT-PCR) was performed using a CFX96 instrument (Bio-
Rad Laboratories, UK). Analysis of samples was performed in
triplicate with each 12-μl reaction containing 6 μl of iTaq™
Universal SYBR® Green Supermix (Bio-Rad Laboratories),
300 nM of each forward and reverse primer (Supplementary
Table 2) and 5 μl of diluted cDNA. Incubation consisted of
polymerase activation and DNA denaturation at 95 °C for
2 min followed by 40 cycles of denaturation at 95 °C for 5 s
with annealing and extension at 60 °C (unless otherwise stated
in Supplementary Table 2) for 30 s followed by fluorescence
detection. Upon completion of thermal cycling, melt-curve
analysis was performed to confirm reaction specificity.
Baseline subtraction and determination of the threshold cycle
(Cq) were performed using Bio-Rad CFX Manager 3.1 (Bio-
Rad Laboratories). Data was subsequently analysed with
qbase + software (Biogazelle, Belgium) using an unpaired t
test. Normalization of expression data was performed using
both Atp5b and Ubc. Of 12 reference genes analysed with the
rat geNorm kit (Primerdesign, UK), both were found to be
comparably highly stable (M = 0.419, CV = 0.145).
Digital Droplet PCR
A total of 20 ng of RNA was reverse transcribed using the
Verso cDNA synthesis kit (Thermo Fisher Scientific, UK).
This was performed according to manufacturer’s instructions.
Random hexamers and anchored oligo-dTwere both included
at a ratio of 3:1 (v/v); 0.5 μl of RT Enhancer per 10 μl reaction
was also included, followed by incubation at 42 °C for 60 min
and 95 °C for 2 min. The cDNAwas subsequently diluted to
100 μl. Further dilutions were performed for the reference
gene Atp5b to avoid saturation of the digital droplet PCR
(ddPCR) system. All reagents and equipment used for
ddPCR were from Bio-Rad Laboratories. Each 20 μl PCR
reaction consisted of 10 μl of QX200™ ddPCR™ Evagreen
Supermix, 250 nM of forward and reverse primer, 5 μl of
diluted cDNA and nuclease free water. This was loaded in to
a DG8™ Cartridge with accompanying DG8™ Gasket and
70 μl of QX200™ Droplet Generation Oil for Evagreen for
droplet generation using a QX200™ Droplet Generator. 96-
well plates were then sealed using pierceable foil plate seals
with a PX1™ PCR plate sealer. A T100™ Thermal Cycler
was used with the following cycling conditions: enzyme acti-
vation for 5 min at 95 °C, followed by 40 cycles of denatur-
ation at 95 °C for 30 s and annealing/extension at 60 °C for
1 min. Signal stabilisation was achieved by cooling to 4 °C for
5 min, heating to 90 °C for 5 min. A ramp rate of 2 °C per
second was required for each step in the PCR. Data was then
obtained using a QX200™ Droplet Reader with ddPCR™
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Droplet Reader Oil and QuantaSoft™ Software, version 1.7.
Normalisation of data was performed by dividing the total
number of transcript copies per 20 μl reaction, by the geomet-
ric mean of Rpl13a and Ubc. Data was analysed using
GraphPad Prism 6.0 using an unpaired t test (p = ≤0.05 con-
sidered statistically significant).
Results
Human Blood Transcriptome Analysis
In order to determine differentially regulated genes, we used
gene microarray analysis to determine the expression of intra-
cellular RNA from whole blood in patients with CNBP and in
healthy controls. Our analysis highlighted a diverse range of
genes that may be perturbed in the development or mainte-
nance of CNBP, which in turn may function as potential bio-
markers of CNBP. These include genes pertaining to immune
function, inflammatory response and extracellular matrix turn-
over (Supplementary Table 3).
Correlation Analysis
We also sought to evaluate how the differentially expressed
genes in this study were correlated with each other in prior
microarray experiments, by analysis of 3900 human 2-colour
arrays obtained from NCBI’s GEO database. Global correla-
tions (i.e. correlations not dependent upon the experimental
condition being studied) between genes suggest their involve-
ment in a common transcriptional response network.
Similarly, negatively correlated gene sets may suggest how
the response under the conditions being studied here
(CNBP) differs from the general trends.
We also analyzed prior correlations among differentially
regulated genes from the 2-colour microarrays, with high
up- and downregulation (Fig. 1). Within the most strongly
upregulated genes, a subset of 3–TIMP1, ORM2 and PROX1
was highly correlated in other experiments. TIMP1 [28–32],
ORM2 [28, 30] and PROX1 [33, 34] have all been found in
proteomic studies in plasma, suggesting that they may have
potential as circulating biomarkers. Literature-mining analysis
of the three genes [35] identifies ANG-1 (angiopoietin, a reg-
ulator of postnatal angiogenesis) as their strongest
commonality.
Expression Analysis Refinement
TIMP1, which was highlighted by our correlation analysis,
dipeptidyl peptidase 3 (DPP3) and melanocortin 1 receptor
(MC1R), all exhibited a strong basis of literature supporting
the role of these genes in pain pathways [36–39]. Similarly,
both orosomucoid 2 (ORM2) and prospero homeobox 1
(PROX1) were present in the correlation analysis, though
PROX1 did not meet any of our other refinement criteria.
Caspase 5 (CASP5) and NLR family CARD domain-
containing protein 4 (NLRC4) were also upregulated in pa-
tients with CNBP, alongside other genes such as toll-like re-
ceptor 5 (TLR5) and clusterin (CLU) (Table 1). We also ob-
served several downregulated transcripts in CNBP patients,
including ring finger protein 185 (RNF185) and lin-28 homo-
log A (LIN28A).
Plasma TIMP1 Quantification
The mean (±SD) level of plasma TIMP1 in healthy control
subjects was 157.3 (±33.2) ng/ml (range: 100.9–233.6 ng/ml);
in contrast, the mean level in CNBP patients (±SD) was 278.4
(±131.4) ng/ml (range: 130.3–546.8 ng/ml). In patients with
CIBP, the mean (±SD) was 147.8 (±75.55) ng/ml (range:
82.56–316.9 ng/ml). Plasma TIMP1 concentrations were
therefore significantly elevated in patients with CNBP when
compared to controls (p = 0.0433) and between patients with
CNBP and CIBP (p = 0.0272) (Fig. 2). There was no signif-
icant change between controls and CIBP patients (p = 0.6682).
When analysing controls, CNBP and CIBP patients together,
significance of elevated TIMP1 was similarly observed
(p = 0.0434). Plasma TIMP1 levels for controls and CNBP
patients were moderately positively correlated to TIMP1
mRNA levels isolated from whole blood (Pearson’s correla-
tion, R = 0.68, p = ≤ 0.05). Age (p = 0.4980) and gender
(p = 0.9948) covariates did not significantly influence
TIMP1 levels, as determined by ANOVA and unpaired t test,
repectively.
SNL Dorsal Horn Expression Analysis
Genes found to be differentially regulated in human blood
were subsequently analysed in the dorsal horn of Sprague–
Dawley rats that had undergone L5 SNL, in conjunction with
their sham counterparts (Table 2). Timp1 expression was no-
tably upregulated (p = 0.0058) 35 days post-SNL. This was
accompanied by a strong trend for upregulation of Mc1r
(p = 0.0847).
Discussion
In the search for biomarkers of pain in the blood, research has
focused on proteomic analysis. It has been reported that the
levels of serum biomarkers correlate with lower back pain and
related functional impairment [40], and that the severity of
polyneuropathy is associated with elevated tumor necrosis
factor-alpha and interleukin-6 (IL-6) [41]. Increased IL-6 has
also been postulated to be a predictive blood biomarker in
herpes zoster, indicating propensity to develop post-herpetic
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neuralgia [42]. A similar study to this, using a CCI model of
NP, found multiple changes in gene expression which corre-
lated between blood and iLDQ, including the inducible T cell
co-stimulator ligand (Icoslg) [19]. ICOSLG was upregulated
in our CNBP cohort, but not in the SNL model of NP. This,
however, may be explained by the use of a contrasting animal
model of NP.
In order to further determine the viability of blood as a
source of CLBP biomarkers, based on the results obtained,
we initially established a list of genes differentially regulated
in human blood in patients with CNBP. To refine and establish
a list of candidate genes, we implemented an enrichment anal-
ysis including a combination of p value and fold change cut-
offs. Although there are limitations to this approach, it did
allow the identification of candidate genes for validation pur-
poses that may have been eliminated with more stringent
criteria. After analysis and refinement of these genes using
our predetermined criteria, 10 of the 15 differentially regulated
genes had existing associations with CNP, pain-related condi-
tions or mechanisms underpinning pain. TIMP1, an inducible,
soluble and secreted protein with cytokine-like properties
[43], was significantly upregulated in the blood of CNBP
patients, highlighted in our correlation analysis and was sup-
ported by a plethora of publications (Table 1). TIMPs function
to inhibit the matrix metalloproteinases (MMPs), a group of
zinc-dependent endopeptidases involved in extracellular matrix
degradation, with several consequential roles in cell–cell inter-
actions, migration and cell proliferation [44]. Such inhibition
has been shown to reverse allodynia post-SNL [45], and after
sciatic nerve injury, theMMP9/TIMP1 axis has been associated
with the nerve regeneration process [46]. Cytokine-mediated
changes in TIMP1 regulation have also been associated with
permeability changes in the subendothelial basement mem-
brane, facilitating neuro-immune interactions through leuko-
cyte migration to the perivascular tissue [47]. Moreover, as a
circulating prognostic marker, many studies have reported
Fig. 1 Prior transcriptional correlations between a subset of highly
downregulated (a) and upregulated (b) genes in CNBP patients using
3900 human 2-colour microarrays. Using a matrix of transcriptional
correlations derived from the analysis of 3900 human 2-colour
microarrays from NCBI’s Gene Expression Omnibus (GEO), which
includes data from a variety of control and experimental samples, gene–
gene Pearson’s correlation coefficients were determined. In the 3900
microarrays used to perform gene–gene correlations, PROX1, ORM2
and TIMP1, we found to positively correlate with each other, which
was supported by our CNP data analysis. In the 2-colour microarray
analysis, other upregulated genes, including CST1, SLC12A9, CDK17,
ARMCX6, were usually negatively correlated (green) to PROX1, ORM2
and TIMP1 (the brightest red squares are the self–self comparisons along
the diagonal). However, our analysis highlighted that both groups of
genes were upregulated, thus providing evidence that PROX1, ORM2
and TIMP1, which are highly correlated in previous experiments, may
be associated with the pathophysiology of CNP andmay function as CNP
biomarkers. ARHGAP11B rho GTPase activating protein 11B, ARMCX6
armadillo repeat containing X-linked 6; C10orf62 chromosome 10 open
reading frame 62; C1orf189 chromosome 1 open reading frame 189;
CDK17 cyclin-dependent kinase 17; CETN2 centrin, EF-hand protein,
2; CST1 cystatin SN; CYP4Z2P cytochrome P450, family 4, subfamily
Z, polypeptide 2, pseudogene; DPP3 dipeptidyl-peptidase 3; DRG1
developmentally regulated GTP binding protein 1; FAM129C family
with Sequence Similarity 129, member C; GSTM2 glutathione S-
transferase mu 2 (muscle); HIST1H2BK histone cluster 1, H2bk; JAZF1
juxtaposed with another zinc finger protein 1; LRRN3 leucine rich repeat
neuronal 3; NPRL3 nitrogen permease regulator-like 3;OR5M3 olfactory
receptor, family 5, subfamilyM, member 3;ORM2 orosomucoid 2;PASK
PAS domain containing serine/threonine kinase; PHOSPHO1
phosphatase, orphan 1; PROX1 prospero homeobox 1; RNF185 ring
finger protein 185; PID1 phosphotyrosine interaction domain
containing 1; PSG4 pregnancy specific beta-1-glycoprotein 4; ROM1
retinal outer segment membrane protein 1; SDHD succinate
dehydrogenase complex, subunit D, integral membrane protein;
SLC12A9 solute carrier family 12 (potassium/chloride transporters),
member 9; TIMP1 tissue inhibitor of metalloproteinases 1; TRAPPC6B
trafficking protein particle complex 6B; XAGE5 X antigen family,
member 5; YOD1YOD1 deubiquitinase; ZNF285 zinc finger protein 285
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disease associations with the MMP9/TIMP1 axis. High serum
MMP9 and low TIMP1 levels were associated with brain lesion
formation in relapsing-remitting MS [48], and a decrease in the
ratio was associated with interferon treatment [49]. This high-
lights the potential for circulating TIMP1 to reflect the activity
of neurological pathology.
We also showed that Timp1 is significantly upregulated in
Sprague–Dawley ipsilateral dorsal horn, which supports its
potential role in the mechanisms underpinning the mainte-
nance or development of CNP and CNBP. Such upregulation
has also been observed after rat spinal cord injury and in the
dorsal root ganglion after sciatic nerve transection (SNT),
28 days after surgery, leading to suggestions that Timp1 may
be involved in pain persistence [36, 50]. Interestingly, this was
observed in the absence of significantly upregulated MMP9, a
target of TIMP1-mediated inhibition [51], which supports
growing evidence that TIMPs may have MMP-independent
functions [52, 53]. In addition, Timp1 was found, alongside a
cluster of secretion-related genes, to be upregulated in the
spinal cord after CCI [37]. This upregulation was not observed
in rats with complete Freund’s adjuvant induced inflammatory
pain, which suggests that Timp1 expression may be discrimi-
natory neuropathic and inflammatory pain, thereby lending
further support to our determination that TIMP1 was signifi-
cantly higher in the plasma of CNBP patients, than those with
CIBP.
DPP3, an enkephalinase and single member of the M49
family of metallopeptidases, exhibits a strong association with
the mechanisms that underpin nociception and was also nota-
bly upregulated in patients with CNBP. DPP3 plays a critical
role in the degradation of enkephalin within the pain modula-
tory system [38] and has been highlighted as a potential target
for the pharmacological management of pain [54], with inhi-
bition of DPP3 by the endogenous opioid peptide spinorphin
demonstrating analgesia in mice [55]. Interestingly, DPP3 ac-
tivity in human cerebrospinal fluid was reduced in subjects
with acute pain when compared to pain free subjects [56].
The structural conformations of DPP3 and the subsequent
changes upon substrate binding have now been elucidated,
giving impetus for furthering the development of novel
DPP3 inhibitors [38, 57]. The potential of DPP3 as a pharma-
cological target, and the potential role of DPP3 as a biomarker
for CNBP, is therefore highly supportive and certainly war-
rants further investigation.
Our results also show an upregulation of CASP5 and
NLRC4. Caspases are endoproteases and regulators of cell
death and inflammation and undergo activation following
the detection of highly conserved pathogen-associated molec-
ular patterns by toll-like receptors (TLRs) and other pattern-
Table 2 qRT-PCR and ddPCR
analysis of gene expression










NM_053736 Caspase 4 a Casp4 0.1951 ↑1.22
NM_053021 Clusterin Clu 0.9990 1.00
NM_053748 Dipeptidyl-peptidase 3 Dpp3 0.4670 ↓1.16
XM_006256260 Inducible T cell co-stimulator ligand Icoslg 0.7920 ↓1.16
NM_001109269 Lin-28 homolog A Lin28a 0.7860 ↑1.30
XM_006255795 Melanocortin 1 receptora Mc1r 0.0847 ↑2.72
NM_001309432 NLR family CARD domain-containing protein 4a Nlrc4 0.5242 ↑1.15
NM_001168524 Rho GTPase activating protein 11A a Arhgap11a 0.8516 ↓1.03
NM_001024271 Ring finger protein 185 Rnf185 0.3900 ↓2.18
NM_053819 TIMP metalloproteinase inhibitor 1 Timp1 0.0058 ↑2.19
NM_001145828 Toll-like receptor 5 Tlr5 0.6820 ↑1.51
a Denotes analysis by ddPCR. The ortholog or closely related gene with high sequence similarity was selected as
appropriate comparison to represent human gene. Genes not described here are either not present within the rat
























Fig. 2 Plasma TIMP1 concentrations in healthy controls and patients
with CIBP or CNBP. Analysis of plasma TIMP1 concentrations in
healthy controls (n = 10), CIBP patients (n = 12) and CNBP patients
(n = 10) was carried out using an ELISA. Diluted plasma samples were
exposed to human TIMP1 monoclonal antibody coated wells and treated
with human TIMP1 antibody conjugated to biotin. After Streptavidin–
Peroxidase treatment, addition of substrate allows for colourmetric
detection at 450 nm. Greater absorbance recordings correlate to higher
plasma TIMP1 levels. *p = ≤0.05 (Mann–Whitney)
Mol Neurobiol
recognition receptors, such as danger-associated molecular
patterns (DAMPs). DAMPs recognise a variety of stimuli,
including ATP-mediated P2X7 receptor activation,
amyloid-β and monosodium urate, leading to associations
with AD [58, 59] and gout-associated sterile inflammation
[60]. This highlights the diverse range of triggers for the for-
mation of the inflammasome, a multiprotein complex and
component of the innate immune system [61]. In addition,
caspase-5 was shown to be upregulated in peripheral blood
of fibromyalgia patients reporting high pain, in contrast to
those with low pain [62] and in patients with ankylosing spon-
dylitis [63].
It has also been shown that mice deficient in NLRC4
inflammasomes showed attenuated carrageenan induced me-
chanical and thermal acute inflammatory hyperalgesia which
coincided with reduced levels of interleukin-1β (p17) and
caspase-1 [64]. Moreover, after rat cervical spinal cord injury,
CASP11 (CASP4), the ortholog of human CASP5, was up-
regulated and activation of the NALP1 inflammasome, which
incorporates CASP11, was observed. Antibody-mediated
neutralisation of a component of this multiprotein complex,
ASC, also resulted in notable tissue sparing and functional
improvement [65]. Taken together with our expression analy-
sis, these findings suggest that upregulation of CASP5 and
NLCR4 may be useful indicators of injury and inflammatory
processes, but further clarification is required to determine
their specificity to CNBP.
MC1Rwas significantly upregulated in patients with CNBP
and trended strongly towards upregulation in the SNL model
of NP. The endogenous melanocortin receptor agonist, alpha
melanocyte-stimulating hormone (α-MSH), is derived from
post-translational processing of proopiomelanocortin. Plasma
levels of α-MSH are tightly regulated, but increases have been
observed in inflammatory disorders, at localised regions of
inflammation [66] and after central administration of α-
MSH, reduced peripheral inflammation has been observed
[67]. In addition, α-MSH has also been shown to inhibit nitric
oxide production in a murine macrophage cell line after lipo-
polysaccharide and interferon-gamma (IFN-γ) stimulation and
exhibited autocrine function leading to modulation of the in-
flammatory response [68].
Point mutations inMC1R are often cited as responsible for
the red-haired phenotype [69]. Individuals with this pheno-
type have been shown to exhibit greater anesthetic require-
ment [70] and increased sensitivity to thermal pain [71]. It
has also been determined that females with two variant
MC1R alleles experience enhanced analgesia with pentazo-
cine, a kappa-opioid receptor agonist [72]. Antagonism of
the melanocortin system has been associated with a reduction
in mechanical and cold allodynia and the reversal of
morphine-induced hyperalgesia [73–75]. Conversely, a role
for MC1R in sex-specific variation in inflammatory pain but
not CNP has also been shown [76]. The influence of MC1R
and the wider melanocortin system on pain perception is clear-
ly diverse, with multiple studies highlighting varying associ-
ations between the melanocortin system, pain and sex-speci-
ficity. Further mechanistic and biomarker analysis must be
undertaken to elucidate and validate the role of MC1R, which
showed upregulation in both CNBP patients and the SNL
model of NP.
We also observed differential regulation of a number of
other genes in the blood of patients with CNBP. After SNT,
activation of the complement cascade has been observed
alongside increased dorsal horn Clu mRNA expression [77].
We did not, however, observe a similar upregulation of Clu in
the SNL model of NP. Upregulation of toll-like receptor 5
(TLR5) was also observed in CNBP patients. Recent studies
have highlighted a potential role for TLR5 in NP, with tlr5−/−
mice exhibiting reduced tactile allodynia after L5 SNL [78].
Although CLU and TLR5 are examples of differentially reg-
ulated genes in human blood that did not translation to the
SNL animal model, with such variability in the animal pain
models available [17], further analysis using alternative
models of NP would be required to assess these genes as
potential translational biomarkers.
We have therefore identified a range of genes differen-
tially regulated in the blood of patients with CNBP, and of
these, TIMP1, DPP3 and MC1R possess a relatively strong
literature basis supporting their role in CNP. Further scru-
tiny of these genes has facilitated the development of the
list of candidate genes that warrants further investigation.
The presence of differential regulation of Timp1 and Mc1r,
in the rat dorsal horn following L5 SNL, suggests that they
may function as translational biomarkers and may be
perturbed in the mechanisms underpinning CNP in the dor-
sal horn. Although there are limitations to the use of dorsal
horn tissue as opposed to the dorsal root ganglion, however
the dorsal horn does provide a disease relevant tissue that
has many potential targets for the development of novel
analgesics [22]. Moreover, many drug targets that have
passed preclinical tests fail in human trials; this is partly
due to the lack of robust translation from the human disease
to animal model; here, we show potential biomarkers of
CNP in humans to be present in a rat model of CNP and
could function as indicators in drug and biomarker devel-
opment. We therefore present TIMP1 as potential transla-
tional biomarker which is able to differentiate between pa-
tients with CNBP and CIBP. Future work and further anal-
ysis are now required to validate these findings with the
aim of deciphering a molecular signature which, alongside
traditional diagnostic methods, has the ability to vastly im-
prove the diagnosis of CNP subtypes. This will include to
explore the role of these biomarkers in other CNP subtypes,
as well as expanding the investigation into preclinical sys-
tems, including different tissues and animal model of neu-
ropathic pain.
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